UBI began its journey in the early 2000s, focusing on the research, development, and manufacture of biosensor test strips used in our hand-held analyzers for the diagnostic point-of-care (POC) market. UBI first developed a blood glucose monitoring product for LifeScan, Inc. (a Johnson & Johnson company) which was launched in 2010 under the global brand of OneTouch® Verio®. This product has sold more than 10 billion tests globally, with hundreds of millions of these tests initially being produced by UBI’s in-house production facility. In 2018, UBI ended its association with OneTouch® Verio® and pivoted this patented technology into other innovations.
In 2011, UBI began developing the Xprecia Stride™ blood coagulation analyzer in collaboration with Siemens Healthineers. Since launched in 2015, Xprecia Stride™ was sold in 36 countries and currently has an install base exceeding 3,500 analyzers, servicing thousands of hospitals around the world.
The Collaboration Agreement with Siemens was terminated. UBI entered into a Commercial and Distribution Agreement and other definitive agreements with Siemens. Pursuant to these agreements, UBI acquired certain assets of Siemens and amongst other things enables UBI the right to pursue partnership and distribution opportunities for point-of-care coagulation products outside of its arrangement with Siemens.
LifeScan gave notice and exercised its right to “convert” its obligation to pay quarterly service fees to UBI. Accordingly, UBI will not receive any further quarterly service fees beyond 2018.
UBI acquires Hemostasis Reference Laboratory business.
Siemens Healthcare Diagnostics receives CE Mark approval and launches the Xprecia Stride™ Coagulation Analyser in Europe. The product has since been launched in key markets including US, Europe, Asia Pacific and The Middle East.
UBI signs long term supply and manufacturing agreement with Siemens Healthcare Diagnostics for manufacture of biosensors for point-of-care (POC) coagulation testing.
LifeScan’s UBI-designed biosensor strip and meter system, OneTouch® Verio®, receives initial regulatory clearance to sell in Europe. The product has since been rolled out globally.
UBI lists on the Australian Securities Exchange. UBI commences establishment of world class biosensor manufacturing facilities at Rowville, Victoria, Australia.
UBI completes deal with LifeScan, Inc, (a Johnson & Johnson company). LifeScan takes ownership of electrochemical cell technologies and grants UBI a licence for these
technologies outside the field of diabetes and blood glucose management generally. LifeScan engages UBI to develop a new blood glucose test.
Universal Biosensors, Inc (UBI) incorporated in Delaware, US. Australian subsidiary, Universal Biosensors Pty Ltd, formed.